Andrew Labelle, MD
Critical Care Medicine · Greenwood Village, CONPI 1891905469
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Medical Device Business Services, Inc. at 30.5% of the total. Reporting peaked in 2022 at $1,163 and has fallen 77.7% since, to $260 in 2025.
Across 61 payments — averaging $56.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$1K
- Pulmonx Corporation$961
- Johnson & Johnson$806
- Inspire Medical Systems, Inc.$119
- Sanofi$97
- GSK$86
- plus $337 from 12 others
What the payments were for
- Travel & lodging$1,75851%
- Food & beverage$1,68749%
- Education$191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 7 | $1,058 |
| Pulmonx Corporation | 8 | $961 |
| Johnson & Johnson(2 entities) | 18 | $806 |
| Inspire Medical Systems, Inc. | 1 | $119 |
| Sanofi | 4 | $97 |
| GSK | 5 | $86 |
| Sunovion Pharmaceuticals Inc. | 5 | $66 |
| ERBE USA Inc | 1 | $43 |
| AstraZeneca | 2 | $41 |
| Merck | 2 | $38 |
| Mylan Specialty L.p. | 1 | $29 |
| Bayer | 1 | $28 |
| Veran Medical Technologies, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $12 |
| Gilead | 1 | $12 |
| United Therapeutics Corporation | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,464 in reported general payments places this provider in the 80th percentile of 141 critical care medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $32,903 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $18,776 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $16,044 |
| Spiriva RespimatTiotropium Bromide | 20 | $14,984 |
| XareltoRivaroxaban | 11 | $12,436 |
| Spiriva HandihalerTiotropium Bromide | 21 | $11,070 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $10,081 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $9,388 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,663 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $2,061 |
| Mycophenolate Mofetil | 11 | $830 |
| Prednisone | 76 | $303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $41 | $42,29056 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $86 | $37,48256 claims |
| Boehringer IngelheimSpiriva Respimat | $12 | $14,98420 claims |
| Johnson & JohnsonXarelto | $806 | $12,43611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 141 critical care medicine providers in Colorado.
Other critical care medicine in Greenwood Village
- Chakradhar KotaruGreenwood Village$61K
- Surit SharmaGreenwood Village$20K
- James HuntGreenwood Village$9K
- Isham HuizarGreenwood Village$6K
- Dylan PearsonGreenwood Village$5K
- Gregory MargolinGreenwood Village$5K
- Ahmad AlsaleemGreenwood Village$3K
- Akshay VijayaramanGreenwood Village$2K
- Fnu Arjun SaradnaGreenwood Village$2K
- Nathaniel PascualGreenwood Village$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.